Home / Science / Jo Cambridge: Disruptor Who Revolutionized Arthritis Treatment
Jo Cambridge: Disruptor Who Revolutionized Arthritis Treatment
29 Aug
Summary
- Jo Cambridge's research led to immunotherapies for rheumatoid arthritis.
- She pursued groundbreaking B-cell depletion research at UCL.
- Cambridge was a mentor and a force of nature in medical research.
Jo Cambridge, a prominent scientist who passed away at 73 from acute myeloid leukaemia, was instrumental in transforming the understanding and treatment of rheumatoid arthritis. Her research at University College London (UCL) yielded immunotherapies now benefiting countless individuals globally.
Born in Perth, Australia, Cambridge excelled academically before moving to London. She earned her PhD in 1984 and dedicated her career to research, notably collaborating with Professor Jonathan Edwards on a revolutionary hypothesis concerning B-cell depletion for autoimmune diseases.
Cambridge's relentless pursuit of evidence underpinned her team's success in proving their controversial theories. Beyond arthritis, her research extended to conditions like Duchenne muscular dystrophy, and she was investigating myalgic encephalomyelitis (ME/CFS) at the time of her passing.
Appointed professor of rheumatology and inflammation in 2015, Cambridge was a deeply respected mentor. She was also a keen horsewoman, animal rights activist, and lifelong vegetarian, known for her vibrant personality.
